Inactive Instrument

News Kythera Biopharmaceuticals Inc

Equities

US5015701056

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2015

Allergan : forecasts second-half revenue above $8 billion

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kythera Biopharmaceuticals : Allergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment for Double-Chin	15-10-08	PU
Kythera Biopharmaceuticals : ® Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss	15-10-08	PU
Allergan : forecasts second-half revenue above $8 billion	15-09-28	RE
KYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss	15-09-22	GL
KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat	15-08-18	GL
KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update	15-08-06	GL
Kythera Biopharmaceuticals : Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration	15-08-05	PR
Allergan and KYTHERA Announce That Pending Transaction Will Now be for All-Cash Consideration	15-08-05	GL
Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA	15-07-27	GL
Kythera Biopharmaceuticals : Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA	15-07-27	PR
KYTHERA Biopharmaceuticals Announces Health Canada Authorization of BELKYRA(TM), a Submental Contouring Injectable Drug(i)	15-07-27	GL
KYTHERA Biopharmaceuticals : Announces US Availability of KYBELLA(TM) -- First FDA-Approved Injectable Treatment for "Double Chin" -- Through KYBELLA(TM) Trained Physicians	15-06-19	PU
KYTHERA Biopharmaceuticals Announces US Availability of KYBELLA(TM) -- First FDA-Approved Injectable Treatment for “Double Chin” -- Through KYBELLA(TM) Trained Physicians	15-06-19	GL
KYTHERA Biopharmaceuticals : Stockholders Encouraged to Contact Securities Law Firm about Takeover	15-06-18	PR
Kythera Biopharmaceuticals : Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of KYTHERA Biopharmaceuticals, Inc. Stockholders	15-06-17	BU
Allergan to Acquire KYTHERA Biopharmaceuticals	15-06-17	GL
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program	15-06-16	GL
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program	15-06-05	GL
KYTHERA Biopharmaceuticals to Present at the Goldman Sachs 36th Annual Global Healthcare Conference	15-06-03	GL
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program	15-05-19	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kythera Biopharmaceuticals Inc

Equities

US5015701056

Summary

Filters